RxDoctor Payments DataLook up a doctor →

Gaurav Upadhyay

Clinical Cardiac Electrophysiology · Chicago, ILNPI 1306973748

Payments from drug & device makers

$784,726in general payments, 2019–2025

Across 1,034 payments — averaging $758.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$312K
  • Medtronic$202K
  • Boston Scientific$102K
  • Abbott$71K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23K
  • Cvrx, Inc.$23K
  • plus $51K from 16 others
$1,750in research payments, 2019–2025

Across 2 payments — averaging $875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$1K
  • Biotronik Inc.$750

What the payments were for

  • Consulting fees$56,43210%
  • Speaking & faculty fees$212,14036%
  • Grants$251,40842%
  • Travel & lodging$46,6378%
  • Food & beverage$26,3424%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784,726 in reported general payments places this provider in the 95th percentile of 158 clinical cardiac electrophysiology providers in Illinois.

See all clinical cardiac electrophysiology providers in Illinois

Medicare billing

Part B allowed, 2024
$202,596
Medicare patients
1,789
Services billed
4,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$87,542
XareltoRivaroxaban25$27,552
EntrestoSacubitril/Valsartan16$12,597
Dofetilide29$5,260
Metoprolol Succinate250$4,899
Flecainide Acetate49$1,287
SotalolSotalol Hcl12$394
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$359
Warfarin Sodium13$342
Carvedilol26$117
Metoprolol Tartrate21$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$87,54280 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 158 clinical cardiac electrophysiology providers in Illinois.

Other clinical cardiac electrophysiology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →